10.1016/j.brainres.2021.147468 18 CaoY.LiY.HeC.YanF.LiJ.-R.XuH.-Z.et al (2021)
PMID: 15124670
Swanton C, Bernard E, Abbosh C, Andre F, Auwerx J, Balmain A, Bar-Sagi D, Bernards R, Bullman S, DeGregori J, Elliott C, Erez A, Evan G, Febbraio MA, Hidalgo A, Jamal-Hanjani M, Joyce JA, Kaiser M, Lamia K, Locasale JW, Loi S, Malanchi I, Merad M, Musgrave K, Patel KJ, Quezada S, Wargo JA, Weeraratna A, White E, Winkler F, Wood JN, Vousden KH, Hanahan D (2024) Embracing cancer complexity: Hallmarks of systemic disease
There is currently no approved starting dose for patients because retatrutide has not yet been licensed for routine prescribing
In January, Novo Nordisks first oral version of Wegovy hit the marketplace, making it an option for individuals who may have been reluctant to use an injectable version, something that may make a difference for young people
GLP-1s: Part of a Nuanced, Personalized Care Approach Consistent with announcements from HLTH USA, a recent article by Renal and Urology News explains that incorporating GLP-1s for CKD treatment requires a nuanced and patient-centered approach